{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:05:30Z","timestamp":1790060730883,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","painmanagementnursing.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pain Management Nursing"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.pmn.2025.04.012","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T15:34:11Z","timestamp":1748532851000},"page":"585-591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Buprenorphine Is Associated With Lower Home Opioid Use and Acute Care Utilization in Sickle Cell Disease"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7307-3927","authenticated-orcid":false,"given":"Charleen","family":"Jacobs-McFarlane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6822-1796","authenticated-orcid":false,"given":"Angela","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"McCrary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7489-9894","authenticated-orcid":false,"given":"Sarah","family":"McCuskee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5395-0809","authenticated-orcid":false,"given":"Mikayla Gordon","family":"Wexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Stidham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Glassberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.pmn.2025.04.012_bib0001","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/bloodadvances.2017006940","article-title":"Depression, quality of life, and medical resource utilization in sickle cell disease","volume":"1","author":"Adam","year":"2017","journal-title":"Blood Advances"},{"issue":"4","key":"10.1016\/j.pmn.2025.04.012_bib0002","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/ejh.13461","article-title":"Characteristics and potential biomarkers of adult sickle cell patients with chronic pain","volume":"105","author":"Albo","year":"2020","journal-title":"European Journal of Haematology"},{"issue":"5","key":"10.1016\/j.pmn.2025.04.012_bib0003","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.pmn.2025.04.012_bib0004","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: Management of acute and chronic pain","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Advances"},{"issue":"13","key":"10.1016\/j.pmn.2025.04.012_bib0005","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jama.2010.378","article-title":"Acute care utilization and rehospitalizations for sickle cell disease","volume":"303","author":"Brousseau","year":"2010","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pmn.2025.04.012_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28766","article-title":"Ambulatory microdose induction of buprenorphine-naloxone in two adolescent patients with sickle cell disease","volume":"68","author":"Buchheit","year":"2021","journal-title":"Pediatric Blood Cancer"},{"issue":"10","key":"10.1016\/j.pmn.2025.04.012_bib0007","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ajh.21515","article-title":"The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization","volume":"84","author":"Carroll","year":"2009","journal-title":"American Journal of Hematology"},{"issue":"1 Suppl 1","key":"10.1016\/j.pmn.2025.04.012_bib0008","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.amepre.2016.02.012","article-title":"Chronic opioid therapy and central sensitization in sickle cell disease","volume":"51","author":"Carroll","year":"2016","journal-title":"American Journal of Preventive Medicine"},{"issue":"1","key":"10.1016\/j.pmn.2025.04.012_bib0009","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/08897077.2021.1967836","article-title":"Opioid treatment programs, telemedicine and COVID-19: A scoping review","volume":"43","author":"Chan","year":"2022","journal-title":"Substance Abuse"},{"issue":"20","key":"10.1016\/j.pmn.2025.04.012_bib0010","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pmn.2025.04.012_bib0011","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7326\/M14-2559","article-title":"The effectiveness and risks of long-term opioid therapy for chronic pain: A systematic review for a National Institutes of Health Pathways to Prevention Workshop","volume":"162","author":"Chou","year":"2015","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1016\/j.pmn.2025.04.012_bib0012","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/16078454.2018.1549801","article-title":"Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: Results of a U.S. survey study","volume":"24","author":"Cronin","year":"2019","journal-title":"Hematology (Luxembourg)"},{"issue":"2","key":"10.1016\/j.pmn.2025.04.012_bib47","doi-asserted-by":"crossref","first-page":"103304","DOI":"10.1016\/j.transci.2021.103304","article-title":"Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy","volume":"61","author":"Curtis","year":"2022","journal-title":"Transfusion and Apheresis Science"},{"issue":"1","key":"10.1016\/j.pmn.2025.04.012_bib0013","doi-asserted-by":"crossref","DOI":"10.52965\/001c.27241","article-title":"Buprenorphine for chronic pain: A safer alternative to traditional opioids","volume":"9","author":"Dalal","year":"2021","journal-title":"Health Psychology Research"},{"issue":"5","key":"10.1016\/j.pmn.2025.04.012_bib0014","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jpain.2016.12.016","article-title":"AAPT diagnostic criteria for chronic sickle cell disease pain","volume":"18","author":"Dampier","year":"2017","journal-title":"The Journal of Pain"},{"issue":"3","key":"10.1016\/j.pmn.2025.04.012_bib0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13430","article-title":"The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management","volume":"105","author":"Darbari","year":"2020","journal-title":"European Journal of Haematology"},{"issue":"Suppl 1","key":"10.1016\/j.pmn.2025.04.012_bib0016","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood-2018-99-111435","article-title":"Assessing the safety and efficacy of converting adults with sickle cell disease from full agonist opioids to buprenorphine","volume":"132","author":"David","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.pmn.2025.04.012_bib0017","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/ajh.26699","article-title":"Converting adults with sickle cell disease from full agonist opioids to buprenorphine: A reliable method with safety and early evidence of reduced acute care utilization","volume":"97","author":"David","year":"2022","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1016\/j.pmn.2025.04.012_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141706","article-title":"Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia","volume":"10","author":"Fitzhugh","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pmn.2025.04.012_bib0019","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/JAN.0000000000000160","article-title":"Nurse practitioner prescriptive authority for buprenorphine: From DATA 2000 to CARA 2016","volume":"28","author":"Fornili","year":"2017","journal-title":"Journal of Addictions Nursing"},{"issue":"8","key":"10.1016\/j.pmn.2025.04.012_bib0020","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: A systematic analysis from the Global Burden of Disease Study 2021","volume":"10","year":"2023","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.pmn.2025.04.012_bib0021","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/SAR.S109919","article-title":"Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: The Bernese method","volume":"7","author":"H\u00e4mmig","year":"2016","journal-title":"Substance Abuse and Rehabilitation"},{"issue":"4 Suppl","key":"10.1016\/j.pmn.2025.04.012_bib0022","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"American Journal of Preventive Medicine"},{"issue":"5","key":"10.1016\/j.pmn.2025.04.012_bib0023","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jpainsymman.2021.04.007","article-title":"Buprenorphine for chronic pain in a pediatric patient with sickle-cell disease","volume":"62","author":"Irwin","year":"2021","journal-title":"Journal of Pain Symptom Management"},{"issue":"16","key":"10.1016\/j.pmn.2025.04.012_bib0024","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/bloodadvances.2020001743","article-title":"Building access to care in adult sickle cell disease: Defining models of care, essential components, and economic aspects","volume":"4","author":"Kanter","year":"2020","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/j.pmn.2025.04.012_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nature Reviews Disease Primers"},{"issue":"2","key":"10.1016\/j.pmn.2025.04.012_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247324","article-title":"Characteristics of sickle cell patients with frequent emergency department visits and hospitalizations","volume":"16","author":"Kidwell","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pmn.2025.04.012_bib0027","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ajh.23912","article-title":"Intensive management of high-utilizing adults with sickle cell disease lowers admissions","volume":"90","author":"Koch","year":"2015","journal-title":"American Journal of Hematology"},{"issue":"5","key":"10.1016\/j.pmn.2025.04.012_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.12419","article-title":"Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the Drug Addiction Treatment Act of 2000 waiver","volume":"5","author":"Lanham","year":"2022","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1016\/j.pmn.2025.04.012_bib0029","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s11606-021-07295-2","article-title":"Transition from oxycodone to buprenorphine\/naloxone in a hospitalized patient with sickle cell disease: A case report","volume":"37","author":"Leyde","year":"2022","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.pmn.2025.04.012_bib48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.genhosppsych.2024.09.013","article-title":"Opioid-related emergency admissions in people with opioid dependence\/use disorder with and without sickle cell disease: An analysis of multi-state insurance claims","volume":"91","author":"Liu","year":"2024","journal-title":"General hospital psychiatry"},{"issue":"1","key":"10.1016\/j.pmn.2025.04.012_bib0030","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2023010813","article-title":"Comparing super-utilizers and lower-utilizers among commercial- and Medicare-insured adults with sickle cell disease","volume":"8","author":"MacEwan","year":"2024","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/j.pmn.2025.04.012_bib0031","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/bloodadvances.2020003456","article-title":"Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection","volume":"5","author":"Minniti","year":"2021","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/j.pmn.2025.04.012_bib0032","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/16078454.2021.1932328","article-title":"Chronic opioid use in patients with sickle cell disease","volume":"26","author":"Mo","year":"2021","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.pmn.2025.04.012_bib0033","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.pmn.2025.04.012_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.24152","article-title":"Evaluation of buprenorphine rotation in patients receiving long-term opioids for chronic pain: A systematic review","volume":"4","author":"Powell","year":"2021","journal-title":"JAMA Network Open"},{"issue":"3","key":"10.1016\/j.pmn.2025.04.012_bib0035","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jpain.2023.09.014","article-title":"Buprenorphine, it works so differently\": Adults with sickle cell disease describe transitioning to buprenorphine for treatment of chronic pain","volume":"25","author":"Prince","year":"2024","journal-title":"Journal of Pain"},{"issue":"Suppl","key":"10.1016\/j.pmn.2025.04.012_bib0036","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.3122\/jabfm.2021.S1.200236","article-title":"Buprenorphine microdose induction for the management of prescription opioid dependence","volume":"34","author":"Robbins","year":"2021","journal-title":"Journal of the American Board of Family Medicine"},{"issue":"Suppl","key":"10.1016\/j.pmn.2025.04.012_bib0037","first-page":"32","article-title":"P-031: Transition from long term high dose full agonist opioids to buprenorphine in the inpatient setting for pediatric patients with sickle cell disease: A modified individualized micro induction approach. A single center experience","volume":"6","author":"Saah","year":"2022","journal-title":"HemaSphere"},{"issue":"7","key":"10.1016\/j.pmn.2025.04.012_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214355","article-title":"Sickle cell disease complications: prevalence and resource utilization","volume":"14","author":"Shah","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pmn.2025.04.012_bib0039","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-148-2-200801150-00004","article-title":"Daily assessment of pain in adults with sickle cell disease","volume":"148","author":"Smith","year":"2008","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1016\/j.pmn.2025.04.012_bib0040","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JXX.0000000000000942","article-title":"What the X? Understanding changes in buprenorphine prescribing regulation","volume":"36","author":"Speight","year":"2024","journal-title":"Journal of the American Association of Nurse Practitioners"},{"issue":"6","key":"10.1016\/j.pmn.2025.04.012_bib0041","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.pmn.2025.04.012_bib0042","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27407","article-title":"Real-world implementation of the David-Carroll buprenorphine protocol for pain management in sickle cell disease","author":"Torres","year":"2024","journal-title":"American Journal of Hematology"},{"issue":"6","key":"10.1016\/j.pmn.2025.04.012_bib0043","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pmn.2025.04.012_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108272","article-title":"Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic","volume":"124","author":"Wang","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.pmn.2025.04.012_bib0045","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/pm\/pnz356","article-title":"Understanding buprenorphine for use in chronic pain: Expert opinion","volume":"21","author":"Webster","year":"2020","journal-title":"Pain Medicine"},{"issue":"1","key":"10.1016\/j.pmn.2025.04.012_bib0046","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/hsw\/hlv085","article-title":"Traumatic exposure history as a risk factor for chronic pain in adult patients with sickle cell disease","volume":"41","author":"Works","year":"2016","journal-title":"Health & Social Work"}],"container-title":["Pain Management Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1524904225001742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1524904225001742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T11:57:34Z","timestamp":1757678254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1524904225001742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1524904225001742"],"URL":"https:\/\/doi.org\/10.1016\/j.pmn.2025.04.012","relation":{},"ISSN":["1524-9042"],"issn-type":[{"value":"1524-9042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine Is Associated With Lower Home Opioid Use and Acute Care Utilization in Sickle Cell Disease","name":"articletitle","label":"Article Title"},{"value":"Pain Management Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmn.2025.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pain Management Nursing. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}